Retatrutide vs Tirzepatide: What Phase 3 Data Shows (2026)

Retatrutide vs Tirzepatide: What the Latest Phase 3 Data Actually Shows

Retatrutide and tirzepatide are both once-weekly injectable medicines developed by Eli Lilly for weight management, but they sit at completely different points in their lifecycle. Tirzepatide is FDA-approved and available by prescription in the United States. Retatrutide is still investigational — it has not been approved by the FDA or any other regulator anywhere in the world, and it cannot legally be sold or compounded for human use.

This comparison is written for adults researching their options before speaking with a prescriber, particularly anyone who has seen retatrutide's headline weight-loss numbers online and is trying to work out whether waiting for it makes sense.

Below you'll find what each drug does at the receptor level, what the published and topline trial data shows on weight loss, side effects and body composition, how both compare to semaglutide, and a clear answer on US availability as of August 2026.

Retatrutide vs Tirzepatide at a Glance

Sources: Eli Lilly topline releases (2025–2026); Jastreboff et al., NEJM 2022; Aronne et al., NEJM 2025. Full references at the end of this article.

What Is Retatrutide?

Retatrutide (development code LY3437943) is a single molecule that activates three separate hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.

The first two receptors are the same ones tirzepatide hits. They work mainly on the intake side of the energy equation — slowing gastric emptying, improving glucose-dependent insulin response, and reducing appetite signalling in the brain.

The third receptor is what makes retatrutide different. Glucagon receptor activation increases hepatic fat mobilisation and raises energy expenditure. In simple terms, GLP-1 and GIP reduce how much you take in; glucagon activity may increase how much you burn.

There is an obvious objection here: glucagon normally raises blood glucose. In retatrutide, the GLP-1 and GIP components appear to offset that effect, which is why the Phase 2 trial reported improvements rather than deterioration in HbA1c and fasting glucose (Jastreboff et al., NEJM, 2023).

What Is Tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist, engineered from the native GIP sequence. It binds GIP receptors with affinity comparable to native GIP, and GLP-1 receptors with roughly five times weaker affinity than native GLP-1 (Jastreboff et al., NEJM, 2022).

It is FDA-approved under two brand names: Zepbound for chronic weight management and obstructive sleep apnea, and Mounjaro for type 2 diabetes. It has a completed Phase 3 programme, a published safety database, an approved label, and years of post-marketing use.

That last point is the one most comparison articles skip past. When a drug is approved, its manufacturing, dosing, contraindications and warnings have been reviewed by regulators. An investigational molecule has none of that, regardless of how good its efficacy numbers look.

Why the Third Receptor Changes the Math

Think of the current generation of weight-management medicines as a ladder of mechanisms:

1. Semaglutide — one receptor (GLP-1). Reduces intake.

2. Tirzepatide — two receptors (GLP-1 + GIP). Reduces intake, with additional metabolic effects.

3. Retatrutide — three receptors (GLP-1 + GIP + glucagon). Reduces intake and may increase expenditure.

Each rung has produced larger average weight loss in trials than the one below it. But each rung has also produced more gastrointestinal side effects and higher discontinuation rates at top doses, which is the trade-off nobody discusses when quoting the headline percentages.

Retatrutide vs Tirzepatide Weight Loss: The Trial Data Side by Side

This is the section most people come for, so here are the actual numbers rather than rounded approximations.

What Retatrutide Achieved in the TRIUMPH Programme

TRIUMPH-1 is the pivotal obesity trial and the one that matters most for approval. Eli Lilly reported topline results on 21 May 2026. It randomised 2,339 adults with obesity, or overweight with at least one weight-related condition and without diabetes, to retatrutide 4 mg, 9 mg, 12 mg or placebo for 80 weeks. Mean baseline weight was 112.7 kg (248.5 lb) with a mean BMI of 40.0 kg/m².

At the 12 mg dose, 62.5% of participants achieved at least 25% weight loss and 45.3% achieved at least 30% — a threshold historically associated with bariatric surgery. In a study extension, a subset of 532 participants with a baseline BMI of 35 or higher who continued to their maximum tolerated dose reached an average of 30.3% (85.0 lb) at 104 weeks.

TRIUMPH-4, reported in December 2025, studied 445 adults with obesity and knee osteoarthritis over 68 weeks. The 12 mg dose produced a mean 28.7% reduction (32.3 kg / 71.2 lb) alongside a 75.8% average improvement in WOMAC pain score.

TRIUMPH-2 (obesity plus type 2 diabetes, n=1,152) and TRIUMPH-3 (obesity plus established cardiovascular disease, n=1,949) both reported positive topline results on 23 July 2026, at up to 20.8% and 22.6% respectively at 80 weeks. Weight loss is consistently lower in populations with diabetes or established cardiovascular disease, which is expected across this entire drug class.

What Tirzepatide Achieved in the SURMOUNT Programme

SURMOUNT-1 enrolled 2,539 adults with obesity or overweight without diabetes and ran for 72 weeks. Mean baseline BMI was 38.0 kg/m².

Under the more conservative treatment-regimen estimand — which counts everyone regardless of whether they stayed on treatment — the 15 mg figure is 20.9%. That is the number most articles quote, which is why you'll see both 20.9% and 22.5% attributed to the same trial. They are not contradictory; they are two different analytical methods applied to the same dataset.

Why You Cannot Read These Numbers as a Head-to-Head Result

Almost every comparison article puts 28.3% next to 20.9% and lets the reader draw the obvious conclusion. That conclusion may well turn out to be correct, but the comparison as presented is not valid evidence, for four reasons:

1. Different durations. TRIUMPH-1 ran 80 weeks. SURMOUNT-1 ran 72. Weight loss curves in this class had not fully plateaued at either endpoint.

2. Different baseline populations. TRIUMPH-1 participants started at a mean BMI of 40.0 versus 38.0 in SURMOUNT-1. Heavier cohorts generally lose a larger percentage of body weight.

3. Different estimands. Comparing retatrutide's efficacy estimand against tirzepatide's treatment-regimen estimand inflates the gap. Like for like, the 12 mg treatment-regimen figure for retatrutide was 25.0%, against tirzepatide's 20.9%.

4. Different eras. SURMOUNT-1 recruited in 2019–2021. TRIUMPH-1 recruited from 2023, into a very different landscape of patient expectations and background care.

The honest summary: retatrutide's data looks stronger, the gap is probably real, and the size of the gap is not yet established.

The One Head-to-Head Trial That Does Exist: TRIUMPH-5

Most articles state flatly that no head-to-head trial exists. That is out of date.

TRIUMPH-5 (NCT06662383) is a randomised, double-blind Phase 3 trial with an estimated 800 participants comparing retatrutide directly against tirzepatide as an active comparator in adults with obesity, running roughly 89 weeks. It is sponsored by Eli Lilly and is currently active but closed to new enrolment.

What does not exist is results. Earliest realistic readout is 2027. Until then, anyone claiming a definitive winner is extrapolating.

Retatrutide vs Tirzepatide vs Semaglutide: Where Each One Sits

Semaglutide is the reference point for this whole category, and it is the only pairing here with genuine randomised head-to-head evidence.

SURMOUNT-5 randomised 751 adults with obesity and without diabetes to maximum tolerated tirzepatide (10 or 15 mg) or maximum tolerated semaglutide (1.7 or 2.4 mg) for 72 weeks. At week 72, mean weight change was −20.2% with tirzepatide versus −13.7% with semaglutide (p<0.001), or 22.8 kg against 15.0 kg. Waist circumference fell 18.4 cm versus 13.0 cm (Aronne et al., NEJM, 2025).

Stacking the three together:

One caveat worth stating plainly: SURMOUNT-5 was open-label, not blinded, and it titrated participants to maximum tolerated dose faster than typical clinical practice would.

Muscle Loss: What the Body Composition Data Does and Does Not Show

This is the area where online comparisons are least reliable, so it needs careful handling.

What is established for tirzepatide.

A DXA substudy of SURMOUNT-1 followed 160 participants to week 72. Body weight fell 21.3%, fat mass fell 33.9%, and lean mass fell 10.9%. Of total weight lost, roughly 75% was fat and 25% was lean — and critically, that same 75/25 split appeared in the placebo group (Look et al., Diabetes, Obesity and Metabolism, 2025). In other words, tirzepatide did not appear to drive disproportionate lean tissue loss; it drove more total weight loss with a similar composition.

What is established for semaglutide. Published DXA analyses have generally reported a less favourable ratio than tirzepatide, with some reviews putting lean mass at around 45% of total weight lost in the STEP programme. Network meta-analysis has flagged both tirzepatide 15 mg and semaglutide 2.4 mg as maximising fat loss while being among the least effective agents for preserving lean mass.

What is not established for retatrutide. No peer-reviewed Phase 3 body composition data has been published. The Phase 2 trial included limited body composition assessment, and none of the four TRIUMPH topline releases have reported DXA outcomes. Any confident claim that retatrutide preserves muscle better than tirzepatide is currently unsupported.

There is a specific mechanistic reason to keep an open mind in both directions. Glucagon receptor activation is catabolic — it breaks tissue down for fuel. Whether that increases lean tissue loss, or whether the increased energy expenditure preferentially targets fat, is an open question that Phase 3 body composition data will need to answer.

What actually moves this number for a patient. Regardless of which drug: adequate protein intake and resistance training. A published case series documented three patients on semaglutide or tirzepatide who prioritised resistance training three to five days per week and higher protein intake; two of them increased lean soft tissue while losing 27–33% of body weight. That is not a controlled trial, and it should not be read as typical, but it shows the ratio is not fixed by the drug alone.

If you take one thing from this section: ask your prescriber about baseline and follow-up body composition assessment, and about a protein and resistance training plan, before you start any agent in this class.

Retatrutide vs Tirzepatide Side Effects

Both drugs share the gastrointestinal profile typical of incretin-based therapy. The differences are in magnitude and in a small number of signals unique to retatrutide.

The Shared Profile

The most common adverse events for both are nausea, vomiting, diarrhoea and constipation. In both programmes these were predominantly mild to moderate, concentrated during dose escalation, and tended to ease at a stable dose.

Both classes carry the boxed warning associated with GLP-1 receptor agonists regarding thyroid C-cell tumours observed in rodents, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2. Pancreatitis and gallbladder disease are recognised, uncommon risks.

Where Retatrutide Differs

Three things stand out in the retatrutide data that are not features of the tirzepatide label:

Dysesthesia. TRIUMPH-1 reported events of altered skin sensation. Lilly described these as generally mild to moderate, with the majority resolving during treatment and most participants continuing therapy. The Phase 2 trial had earlier reported cutaneous hyperesthesia and skin sensitivity in roughly 7% of retatrutide participants versus 1% on placebo.

Urinary tract infections. Also reported in TRIUMPH-1 as generally mild to moderate and mostly resolving on treatment.

Heart rate. The Phase 2 trial documented dose-dependent increases in heart rate that peaked around week 24 and declined afterwards.

Tolerability vs Efficacy: The Real Trade-off

This is the part that gets buried, and it may matter more to an individual patient than the headline efficacy gap.

Discontinuation due to adverse events in TRIUMPH-1 was 4.1% at 4 mg, 6.9% at 9 mg and 11.3% at 12 mg, against 4.9% on placebo. So the 12 mg dose that produced the 28.3% figure also caused more than one in ten participants to stop treatment because of side effects.

For context, in SURMOUNT-5 only 1.6% of tirzepatide participants discontinued due to adverse events, and gastrointestinal events specifically caused discontinuation in 2.7%.

Notably, the 4 mg retatrutide dose — reached after a single escalation step — still produced 19.0% weight loss at 80 weeks with a discontinuation rate lower than placebo. Analysts covering the readout have suggested tirzepatide is likely to remain the default option for most patients on balance of efficacy and tolerability, with retatrutide potentially finding its place at the higher end of the BMI spectrum or in patients with specific complications.

Can You Get Retatrutide in the United States Right Now?

No. And this section is the most important one in the article.

Retatrutide is not approved by the FDA, EMA, MHRA, Health Canada or any other regulator. Eli Lilly stated in its Q2 2026 results that the clinical data package is now complete to support registrations in obesity, obstructive sleep apnea and knee osteoarthritis pain, with a Biologics License Application planned for submission to the FDA in the first quarter of 2027. Assuming a standard review, a US decision would realistically fall in late 2027 or 2028. No approval date has been confirmed by Lilly or the FDA.

Why "Research-Use Only" Retatrutide Is a Serious Risk

Retatrutide is being sold online right now, typically labelled "research use only" or offered through med spas and wellness clinics. This is not a grey area.

The FDA has stated that sales of unapproved retatrutide to consumers are illegal, that retatrutide cannot lawfully be compounded, and that so-called research-use-only products are of unknown quality and may be harmful.

On 12 August 2026, Eli Lilly filed six lawsuits against US entities selling black-market retatrutide, naming a California med spa, a Texas compounding pharmacy and four online peptide sellers. Lilly reported that it has referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general and licensing boards, and flagged more than 14,000 listings across over 100 countries. Lilly's chief medical officer described the material being sold as unverified and unapproved.

The enforcement data gives a sense of scale. US Customs and Border Protection intercepted more than 690 shipments totalling over 31,000 units of illicit GLP-1 products in fiscal year 2025; in July 2026 alone, seizures exceeded 1,400 with nearly 90,000 vials intercepted. In October 2025, the UK's MHRA seized 2,000 pen injectors purporting to contain retatrutide and tirzepatide from a single site, along with tens of thousands of empty pens ready to be filled.

Products bought this way may be contaminated, may contain more or less active ingredient than stated, or may contain none at all. There is no pharmacist, no prescriber oversight, no adverse event reporting, and no recourse.

The Two Legitimate Routes

1. Clinical trial enrolment. The numbered TRIUMPH obesity trials have closed, but studies remain open in other indications. Check ClinicalTrials.gov and confirm status before applying.

2. Manufacturer early access. Lilly has confirmed it will allow a limited number of patients meeting specific medical criteria to apply for pre-approval access. Eligibility is narrow.

If neither applies to you, the realistic options today are the approved medicines — and that is not a consolation prize. Tirzepatide's 20–22% average is the best result available under medical supervision in the US right now.

Who Should Avoid These Medications

Contraindications apply to tirzepatide as an approved product, and to retatrutide as an investigational agent under trial exclusion criteria. This list is a starting point, not a complete one. Only a licensed clinician reviewing your full history can determine suitability.

Do not use, or discuss carefully with your prescriber first, if any of the following apply:

• Personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). This is an absolute contraindication for tirzepatide.

• Pregnancy, planning pregnancy, or breastfeeding. These medicines are not recommended in pregnancy, and weight loss during pregnancy is not advised. Discuss contraception, as GLP-1 therapy can affect absorption of oral contraceptives.

• Prior serious hypersensitivity reaction to tirzepatide or any component of the formulation.

• History of pancreatitis. Discontinue and seek care if severe, persistent abdominal pain develops.

• Type 1 diabetes, or a history of diabetic ketoacidosis.

• Diabetic retinopathy, particularly if proliferative — rapid glucose improvement can worsen retinopathy and requires monitoring.

• Severe gastrointestinal disease, including gastroparesis or inflammatory bowel disease.

• Severe renal or hepatic impairment, or a history of significant dehydration-related kidney injury.

• Active gallbladder disease.

• Concurrent use of insulin or sulfonylureas — dose adjustment is usually required to reduce hypoglycaemia risk.

• A current or past eating disorder.

• Planned surgery or procedures requiring anaesthesia — delayed gastric emptying affects fasting protocols, so tell your surgical and anaesthesia team.

Medical Disclaimer

The information provided on this page is for educational purposes only and does not constitute medical advice. Individual results may vary. Retatrutide is an investigational medicine that is not approved by the U.S. Food and Drug Administration and cannot be legally prescribed, compounded or sold for human use in the United States. Please consult a qualified medical practitioner before starting, stopping or changing any medication to determine what is suitable for your specific health condition.

Compounded medications are not FDA-approved finished drug products and are not the same as, nor equivalent to, Ozempic®, Wegovy®, Mounjaro® or Zepbound®. A licensed prescriber will discuss the differences with you during consultation.

What This Means If You Are Deciding Today

Retatrutide's Phase 3 data is the strongest weight-loss result published for any obesity medicine so far. If it reaches the market, it will likely reset expectations, particularly for people with higher BMI or with knee osteoarthritis or fatty liver disease.

But it is at least eighteen months from a US decision, the trade-off in tolerability at the top dose is real, and every product currently sold as retatrutide in the US is illegal and unverified.

Tirzepatide is the strongest option that a licensed US prescriber can legally offer today, with a completed Phase 3 programme, published body composition data, and a head-to-head win over semaglutide.

If you want to know whether a GLP-1 or dual-agonist programme is clinically appropriate for you, our free eligibility assessment takes about five minutes and is reviewed by a licensed US physician. You can also read more about tirzepatide programmes or compare it with semaglutide before you decide.

[Insert clinic-specific line here before publishing — e.g. "At ZynoxRX, our prescribing clinicians typically start patients at the lowest effective dose and escalate on a four-week schedule, with a check-in at every refill." This is a mandatory E-E-A-T first-person signal.]

Frequently Asked Questions

Is retatrutide better than tirzepatide?

On trial data so far, retatrutide has produced larger average weight loss — 28.3% at 80 weeks versus 22.5% at 72 weeks for tirzepatide. However, these figures come from separate trials with different populations and durations, so they are not a direct comparison. The head-to-head trial, TRIUMPH-5, has not reported results. Tirzepatide is also approved and available, while retatrutide is not.

When will retatrutide be FDA approved?

Eli Lilly has stated it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. Under a standard review timeline, a decision would likely come in late 2027 or 2028. No approval date has been confirmed by Lilly or the FDA, and timelines can change.

Can I buy retatrutide legally in the US?

No. The FDA has stated that sales of unapproved retatrutide to consumers are illegal and that it cannot be lawfully compounded. Products sold as "research use only" are unregulated and of unknown quality. The only legitimate routes are clinical trial enrolment or Lilly's limited pre-approval access programme. Always speak to a licensed prescriber before considering any weight-management medication.

Does retatrutide cause more muscle loss than tirzepatide?

There is no published Phase 3 body composition data for retatrutide, so this cannot be answered from evidence yet. Tirzepatide's SURMOUNT-1 DXA substudy found roughly 75% of weight lost was fat and 25% lean, matching the placebo ratio. Because glucagon receptor activity is catabolic, lean mass is a question researchers are watching closely in the TRIUMPH programme. Adequate protein and resistance training are the main patient-side levers regardless of drug.

What are the main side effects of retatrutide vs tirzepatide?

Both cause nausea, vomiting, diarrhoea and constipation, generally mild to moderate and worst during dose escalation. Retatrutide trials additionally reported dysesthesia (altered skin sensation), urinary tract infections, and dose-dependent heart rate increases. Discontinuation due to side effects was 11.3% at retatrutide 12 mg, compared with 1.6% for tirzepatide in SURMOUNT-5. Report any severe or persistent symptoms to your prescriber.

How does semaglutide compare to both?

Semaglutide targets one receptor and produced roughly 15% average weight loss in its pivotal trial. In the SURMOUNT-5 head-to-head trial, tirzepatide achieved 20.2% versus semaglutide's 13.7% at 72 weeks. Retatrutide's trial figures are higher still, but have not been compared directly to either.

Is a lower retatrutide dose worth considering instead of the highest one?

In TRIUMPH-1, the 4 mg dose produced 19.0% average weight loss at 80 weeks with a discontinuation rate lower than placebo — comparable efficacy to tirzepatide with better tolerability than the 12 mg arm. If retatrutide is approved, dose selection is likely to be an individual clinical decision rather than a default to the maximum.

Should I stop tirzepatide and wait for retatrutide?

This is a decision for you and your prescriber, not something to decide from an article. Retatrutide is at least eighteen months from a possible US decision, approval is not guaranteed, and stopping treatment in this class is generally followed by weight regain. If your current treatment is not producing the results you expected, discuss dose optimisation or alternatives with your clinician first.

References

Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. P. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine, 393(1). https://doi.org/10.1056/NEJMoa2416394

Eli Lilly and Company. (2025, December 11). Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial [Press release]. https://investor.lilly.com

Eli Lilly and Company. (2026, May 21). Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial [Press release]. https://investor.lilly.com

Eli Lilly and Company. (2026, August 5). Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress [Form 8-K]. U.S. Securities and Exchange Commission.

Eli Lilly and Company. (2026, August 12). Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market [Press release]. https://investor.lilly.com

Goldney, J., Hamza, M., Surti, F., Davies, M. J., & Papamargaritis, D. (2025). Triple agonism based therapies for obesity. Current Cardiovascular Risk Reports. https://doi.org/10.1007/s12170-025-00770-z

Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972

Look, M., et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16275

Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., Haupt, A., & Hartman, M. L. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: A randomized phase 2a trial. Nature Medicine, 30. https://doi.org/10.1038/s41591-024-03018-2

U.S. Food and Drug Administration. (2026). Medical devices safety and unapproved drug products. https://www.fda.gov

U.S. National Library of Medicine. (2026). A study of retatrutide (LY3437943) compared to tirzepatide (LY3298176) in adults who have obesity (NCT06662383). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06662383